Personalized care for severe lung failure (ARDS) and sepsis
Advancing Precision Medicine for ARDS and Sepsis
This project uses blood markers and routine clinical information to match treatments to people with ARDS or sepsis so each person gets the care most likely to help them.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11310714 on NIH RePORTER |
What this research studies
Researchers have found two biological subtypes of ARDS and sepsis, called hyperinflammatory and hypoinflammatory, that behave differently and respond differently to treatments. This work uses patients' clinical data and blood protein tests to identify those subtypes and refine quick tests doctors could use at the bedside. The team will study existing patient samples and clinical records and link those biological signatures to responses to therapies like fluids, ventilation strategies, statins, and corticosteroids. The aim is to give ICU doctors clearer guidance so patients receive treatments tailored to their body's specific response pattern.
Who could benefit from this research
Good fit: Ideal participants are people hospitalized with sepsis or ARDS in the ICU who can provide clinical data and blood samples for testing.
Not a fit: People without sepsis or ARDS, or those who cannot provide blood samples or clinical data, are unlikely to benefit directly from this work.
Why it matters
Potential benefit: If successful, this approach could help doctors pick treatments that lower the risk of death and improve recovery for people with ARDS or sepsis.
How similar studies have performed: Previous research has repeatedly identified the hyperinflammatory and hypoinflammatory subtypes and shown they respond differently to several therapies, though routine bedside use of these signatures is still being developed.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Calfee, Carolyn — University of California, San Francisco
- Study coordinator: Calfee, Carolyn
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.